Tags : P-IIIB/IV

Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study

Shots: The P-IIIb/IV PROPEL study involves assessing of Adynovate in prophylaxis targeting two different FVIII trough levels (1–3% REF/ 8–12% ELE) in prior treated patients with severe hemophilia A The P-IIIb/IV PROPEL study resulted in enhancing a patient’s PK profile by targeting ELE vs REF, patients with zero bleed (62% vs % vs 42%), reduction […]Read More

Eli Lilly to Report Positive Results of Taltz (ixekizumab) in

Shots: The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks. The P-IIIb/IV SPIRIT-H2H study results: met its 1EPs & 2Eps i.e, @24wks. reduction by 50% in disease activity as defined by ACR50; PASI100 (36% vs 28%) & superior to Humira, ACR50 […]Read More